Novo Nordisk(US:NVO) Prnewswireยท2025-08-15 16:14Core Insights - The complaint alleges that Novo Nordisk and its executives violated federal securities laws by making false or misleading statements regarding the company's growth potential and market penetration capabilities [2] - On July 29, 2025, Novo announced a reduction in its sales and profit outlook for the second half of 2025, attributing this to lower growth expectations for its products Wegovy and Ozempic, which led to a significant stock price decline of approximately 21.83% in one day [3] Group 1 - The complaint claims that Novo's stated potential to capitalize on the compounded market significantly understated the impact of the personalization exception to the compounded GLP-1 exclusion [2] - The company allegedly overstated the likelihood of patients switching to Novo's branded alternatives and the overall potential GLP-1 market [2] - Following the announcement of lowered growth expectations, Novo's stock price fell from $69.00 to $53.94 per share, marking a dramatic decline [3] Group 2 - The lead plaintiff in the class action is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [4] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4] - The law firm encourages individuals with information regarding Novo's conduct to come forward, including whistleblowers and former employees [5]